In 2023, sales of antiarrhythmic medicines in Germany stood at 68.2 million USD. The forecast for the next few years suggests a slight but steady decline, with sales expected to reach 67.8 million USD in 2024, 67.4 million USD in 2025, 67.0 million USD in 2026, 66.7 million USD in 2027, and 66.5 million USD in 2028.
Year-on-year variation percentages show a gradual decrease. From 2024 to 2025, the value is expected to drop by 0.59%. The decline continues with a 0.59% decrease from 2025 to 2026, a 0.45% decrease from 2026 to 2027, and a 0.30% decrease from 2027 to 2028. The compound annual growth rate (CAGR) from 2024 to 2028 is -0.48%, highlighting a consistent downtrend over this five-year period.
Future trends to watch for include potential advancements in alternative treatments, the impact of upcoming regulations, and the influence of newer technologies on patient adherence and drug effectiveness. Additionally, monitoring demographic shifts and the prevalence of heart-related conditions will be crucial in understanding the long-term demand for antiarrhythmic medicines.
